 Proactive Investors USA & Canada |
AstraZeneca to join Rigel in asthma drug venture
The News Journal AstraZeneca will join with Rigel Pharmaceutical Inc. to develop a treatment for chronic asthma that could be worth $100 million, if the drug can manage the … AstraZeneca partners with Rigel on asthma drug AstraZeneca and Rigel strike asthma deal worth up to $100M AstraZeneca And Rigel Sign Worldwide License Agreement For A … |
View full post on asthma – Google News